People · Operator
Named in public records as an officer, director or promoter · active 2022–2025 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Arsenal Biosciences, Inc. | — | Biotechnology | Series D+ | $579.2M | $3.5B | 2022 |
| Kamau Therapeutics, Inc. | — | Pharma | Series A | $5.0M | $17.4M | 2025 |
Valentin Barsan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Valentin Barsan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Beth Seidenberg | 1 | 15 |
| Brook Byers | 1 | 13 |
| Sean Parker | 1 | 10 |
| Raymond Kelleher | 1 | 4 |
| Matthew Fust | 1 | 4 |
| James Ahlers | 1 | 2 |
| Matthew Porteus | 1 | 2 |
| Ness Bermingham | 1 | 1 |
| Kenneth Drazan | 1 | 1 |
| Irene Pleasure | 1 | 1 |
| Margaret Nibbi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.